We are a specialty generic pharmaceutical company engaged in the formulation and commercialization of both controlled release ("CR") and immediate release ("IR") products utilizing our proprietary drug delivery technologies. By applying our technologies to selected generic prescription pharmaceuticals, we seek to duplicate the release characteristics of these drugs in order to manufacture and market versions that can be substituted for branded products. We intend to develop and use our drug delivery technologies to commercialize a portfolio of generic pharmaceutical products. In the near future, we also plan to apply our drug delivery technologies to the development of proprietary branded drugs. Abrika has been in operation since May 2002 under the direction of Alan Cohen, founder and retired CEO and Chairman of Andrx Corporation.